Abstract
<h3>To the Editor.</h3> —The Diabetes Control and Complications Trial (DCCT) Research Group<sup>1</sup>has recently published data that suggest that intensive insulin therapy for management of insulin-dependent diabetes mellitus (IDDM) may be well within the range of cost-effectiveness considered to represent good value. The DCCT group needs to be commended for such a thorough analysis and for providing yet another dimension to our understanding of the public health aspects of diabetes. Economic analysis alongside randomized clinical trials offer another important perspective to trial findings and can provide a rational means of assessing the implications of translating research information into practice. Given the importance of this study, it would be useful to have the insights of the authors regarding 3 aspects of the analysis. First, while clinical trials may offer data that are internally valid, they are often not readily generalizable—an issue that may be particularly important when it comes to
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
